ArriVent is a startup based in the United States, most recent round Series B, 3 tracked investors.
Based in the United States, ArriVent is a startup founded in 2020. Its most recent tracked round is Series B. Brouky records 3 investors associated with the company.
ArriVent is a clinical-stage biopharmaceutical company focused on the global development of innovative cancer therapies, particularly targeting EGFR mutations in non-small cell lung cancer through its lead drug firmonertinib.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.